TEL AVIV, Israel


,


Nov. 28, 2022


/PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that management will participate in the 12

^th

Annual LifeSci Partners Corporate Access Event, taking place

January 9-11, 2023

, in

San Francisco, CA

, and will be available for one-one-one meetings on

January 11, 2023

. Learn more about the event and schedule an in-person meeting with BioLineRx management

here

.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a pre-commercial-stage biopharmaceutical company focused on oncology. The Company’s lead development program, motixafortide, a novel selective inhibitor of the CXCR4 chemokine receptor, may support diverse therapeutic approaches in oncology and other diseases.  APHEXDA® (motixafortide) was successfully evaluated in a Phase 3 study in stem cell mobilization for autologous transplantation in multiple myeloma patients, has reported positive results from a pre-planned pharmacoeconomic study in the U.S., and has had its NDA submission accepted by the FDA with a PDUFA date of

September 9, 2023

. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of pancreatic cancer (PDAC) in combination with KEYTRUDA® and chemotherapy and is currently being studied in combination with LIBTAYO® and chemotherapy as a first-line PDAC therapy. A randomized phase

2b

study with 200 patients in combination with an anti-PD1 and chemotherapy as a first-line PDAC therapy will initiate in 2023. BioLineRx is also developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study. For additional information on BioLineRx, please visit the Company’s website at

www.biolinerx.com

, where you can review the Company’s SEC filings, press releases, announcements, and events.

Contacts:

United States




John Lacey


BioLineRx

+1-781-392-5514


[email protected]

Tim McCarthy


LifeSci Advisors, LLC


[email protected]

Israel




Moran Meir


LifeSci Advisors, LLC

+972-54-476-4945


[email protected]

View original content:

https://www.prnewswire.com/news-releases/biolinerx-to-participate-in-the-12th-annual-lifesci-partners-corporate-access-event-301688220.html

SOURCE BioLineRx Ltd.